Yu Zhang, MD, PhD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Research
Publications
2024
GAD65 tunes the functions of Best1 as a GABA receptor and a neurotransmitter conducting channel
Wang J, Owji A, Kittredge A, Clark Z, Zhang Y, Yang T. GAD65 tunes the functions of Best1 as a GABA receptor and a neurotransmitter conducting channel. Nature Communications 2024, 15: 8051. PMID: 39277606, PMCID: PMC11401937, DOI: 10.1038/s41467-024-52039-5.Peer-Reviewed Original ResearchConceptsCl- currentsRetinal pigment epithelial cellsIsoform of glutamic acid decarboxylasePigment epithelial cellsGlutamic acid decarboxylaseG-aminobutyric acidBestrophin-1BEST1GABA receptorsTransport metabolonEpithelial cellsGAD65Glutamate metabolizing enzymesAcid decarboxylaseGAD67Bestrophin channelsGABAExtracellular sitesNo effectAnion channelMetabolic enzymesPhysiological roleGlutamateCellsBestrophinSpontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells
Wang R, Hu P, Wang F, Lyu J, Ou Y, Edderkaoui M, Zhang Y, Lewis M, Pandol S, Zhau H, Chung L. Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells. Cancers 2024, 16: 951. PMID: 38473313, PMCID: PMC10931070, DOI: 10.3390/cancers16050951.Peer-Reviewed Original ResearchProstate cancer cellsStromal cell lineBystander cellsCancer cellsCell linesTumor cell heterogeneityFusion hybridsMesenchymal stromal cellsCell fusionTumor microenvironmentGenomic hybridizationTumor cellsMesenchymal stromal cell lineStromal cellsTumorDerivative clonesPhenotypic heterogeneityCell compartmentPhenotypic diversificationGenomic makeupBehavioral phenotypesCell heterogeneitySpontaneous fusionDerivative subclonesSublinesOvercoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate
Ou Y, Chu G, Lyu J, Yin L, Lim A, Zhai N, Cui X, Lewis M, Edderkaoui M, Pandol S, Wang R, Zhang Y. Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate. Molecular Pharmaceutics 2024, 21: 873-882. PMID: 38229228, PMCID: PMC11025579, DOI: 10.1021/acs.molpharmaceut.3c00993.Peer-Reviewed Original ResearchConceptsProstate cancerTherapeutic resistanceTarget PC cellsAndrogen receptor statusTraditional systemic treatmentsSuppressed xenograft tumor formationProstate cancer therapyCastration-resistant formTumor cell targetsPC cellsSignificant side effectsCancer-related deathsCell deathHeptamethine carbocyanine dyeXenograft tumor formationPC cell linesXenograft tumor modelReceptor statusHormone therapySystemic treatmentSafety profileTumor cellsChemotherapeutic drugsTumor modelCancer therapy